BioCryst Pharmaceuticals
BCRX
88 hedge funds and large institutions have $461M invested in BioCryst Pharmaceuticals in 2014 Q1 according to their latest regulatory filings, with 26 funds opening new positions, 26 increasing their positions, 21 reducing their positions, and 13 closing their positions.
100% more first-time investments, than exits
New positions opened: 26 | Existing positions closed: 13
75% more capital invested
Capital invested by funds: $264M → $461M (+$197M)
43% more call options, than puts
Call options by funds: $10.9M | Put options by funds: $7.64M
24% more repeat investments, than reductions
Existing positions increased: 26 | Existing positions reduced: 21
17% more funds holding
Funds holding: 75 → 88 (+13)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$68.1M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$16.9M |
| 3 |
State Street
Boston,
Massachusetts
|
+$16.8M |
| 4 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
+$9.6M |
| 5 |
TAM
THB Asset Management
Norwalk,
Connecticut
|
+$3.21M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BBA
Baker Bros. Advisors
New York
|
-$8.88M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
-$8.23M |
| 3 |
D.E. Shaw & Co
New York
|
-$3.96M |
| 4 |
TC
TFS Capital
West Chester,
Pennsylvania
|
-$3.8M |
| 5 |
SGAM
Smith Group Asset Management
Dallas,
Texas
|
-$2.22M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
101
BlackRock
New York
| – | +$149 | +14 | New |
|
BCRX Hedge Fund Activity: Q1 2014 in Review
88 of the 3,462 institutional investors tracked by Wall St. Rank reported a position in BioCryst Pharmaceuticals (BCRX) for Q1 2014, worth a combined $461M — up 75% from $264M a quarter earlier.
Buyers outnumbered sellers: 26 funds opened new BCRX positions and 13 closed out — a net gain of 13 holders — while 26 added to existing stakes and 21 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $68.1M. The largest seller was Baker Bros. Advisors, cutting an estimated $8.88M.
- 88 institutional investors held BioCryst Pharmaceuticals (BCRX) as of Q1 2014, up from 75 in Q4 2013.
- Funds reported $461M of BioCryst Pharmaceuticals stock for Q1 2014, up 75% quarter-over-quarter.
- 26 funds opened new BioCryst Pharmaceuticals positions in Q1 2014 and 13 closed out, a net change of +13 holders.
- The largest BioCryst Pharmaceuticals buyer in Q1 2014 was Fidelity Investments, an estimated $68.1M added.
- The largest BioCryst Pharmaceuticals seller in Q1 2014 was Baker Bros. Advisors, an estimated $8.88M sold.
Based on aggregated 13F filings for Q1 2014.